Visão geral da empresa
A clinical-stage life sciences company, Cardiol Therapeutics Inc. is dedicated to the development of anti-fibrotic and anti-inflammatory therapies designed specifically for the treatment of heart diseases. The firm operates within the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry, a classification that reflects its focus on creating specialized pharmaceutical solutions rather than mass-market commodities. The company currently holds a market capitalization of $154.12M, while data on annual revenue and employee count are not available in the provided financial records. These valuation figures indicate that the market prices the entity as a high-risk, early-stage biotechnology venture, where value is derived primarily from future potential rather than established historical earnings or operational scale.
Saúde financeira
The company reports a net income of $-33,818,872 and an EBITDA of $-34,278,296, while annual revenue data is unavailable, suggesting the firm is not yet profitable. The significant gap between revenue and net income, alongside the absence of revenue figures, reveals a cost structure dominated by heavy research and development expenditures typical of clinical-stage enterprises. Free cash flow stands at $-13,026,343, indicating that the company is burning cash to fund its operations and pipeline advancement rather than generating liquidity. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are recorded at 0.0%, which indicates that the company has not yet achieved positive profitability from its sales or operations. In terms of liquidity, the firm holds $21.42M in cash against total debt of $125,523, resulting in a debt-to-equity ratio of 0.70. Despite the low absolute debt level, the reliance on cash reserves highlights a balance sheet that is currently leveraged in a manner common for pre-commercial biotech firms. The current ratio of 4.16 demonstrates strong short-term liquidity, suggesting the company possesses ample current assets to cover its immediate obligations. Return on Equity is -158.8% and Return on Assets is -77.3%, metrics that reveal that management effectiveness is currently measured by the ability to preserve capital while driving clinical progress rather than generating shareholder returns.
Avaliação de valorização
The trailing P/E ratio is not available due to the lack of earnings, whereas the forward P/E is listed at -8.11, implying that the market expects earnings to remain negative or that valuation models are adjusting for anticipated losses. The price-to-book ratio is 17.60, indicating that the market is pricing the company at a significant premium over its book value, a characteristic often seen in firms with valuable intangible assets like clinical data and intellectual property. Alternative valuation metrics such as the price-to-sales ratio, which is not available, and the EV/EBITDA of -3.88 suggest that traditional multiple-based comparisons are not applicable until the company generates positive cash flows. The stock has traded between a 52-week high of $1.59 and a 52-week low of $0.80, placing the current valuation within a wide historical range that reflects high volatility in the biotech sector. The beta value of 0.43 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market fluctuations than typical large-cap equities.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both marked as not available, preventing a direct comparison of growth rates between top-line sales and bottom-line profits. Since the company does not pay dividends, the dividend yield and payout ratio are effectively 0.0%, meaning the firm reinvests all available resources back into research, development, and clinical trials to fuel future expansion. The overall growth and income profile is defined by a lack of current profitability and dividend generation, with all capital directed toward advancing the lead product candidate CardiolRx through Phase III clinical trials. This reinvestment strategy is standard for clinical-stage entities that prioritize pipeline advancement over immediate financial distributions to shareholders.